Myasoedova E, Davis JM, Crowson CS, Gabriel SE: Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010, 12: 379-385.
Article
PubMed
Google Scholar
Gonzalez A, Kremers HM, Crowson CS, Nicola PJ, Davis JM, Therneau TM, Roger VL, Gabriel SE: The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007, 56: 3583-3587.
Article
PubMed
Google Scholar
Kuper HH, van Leeuwen MA, van Riel PL, Prevoo ML, Houtman PM, Lolkema WF, van Rijswijk MH: Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol. 1997, 36: 855-860.
Article
CAS
PubMed
Google Scholar
Curtis JR, Singh JA: Use of biologics in rheumatoid arthritis: current and emerging paradigms of care (review). Clin Ther. 2011, 33: 697-707.
Article
Google Scholar
Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010, 69: 631-637.
Article
PubMed
PubMed Central
Google Scholar
Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010, 69: 964-975.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cush JJ: Early rheumatoid arthritis - Is there a window of opportunity?. J Rheumatol. 2007, 34: 1-7.
Google Scholar
Breedveld F: The value of early intervention in RA - a window of opportunity. Clin Rheumatol. 2011, 30: 33-39.
Article
Google Scholar
Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000, 343: 1594-1602.
Article
CAS
PubMed
Google Scholar
Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50: 353-363.
Article
CAS
PubMed
Google Scholar
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alfa monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45.
Article
CAS
PubMed
Google Scholar
Keystone EC, Genovese MC, Klareskog L: Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2009, 68: 789-796.
Article
CAS
PubMed
Google Scholar
Keystone EC, van der Heijde DM, Mason D, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum. 2008, 58: 3319-3329.
Article
CAS
PubMed
Google Scholar
Emery P, Keystone EC, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008, 67: 1516-1523.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54: 2793-806.
Article
CAS
PubMed
Google Scholar
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005, 52: 1020-1030.
Article
CAS
PubMed
Google Scholar
Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S: Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006, 54: 3119-3125.
Article
PubMed
Google Scholar
Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH: Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009, 36: 1429-1441.
Article
CAS
PubMed
Google Scholar
Smolen JS, Avila JCM, Aletaha D: Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: Disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012, 5: 687-693.
Article
Google Scholar
Aletaha D, Alasti F, Smolen JS: Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Ann Rheum Dis. 2013, 72: 7-12.
Article
CAS
PubMed
Google Scholar
Arnett FC, Edworthy SM, Bloch DA: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
Article
CAS
PubMed
Google Scholar
Visser K, Goekopp-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF: A matrix risk model for the prediction of rapid radiological progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010, 69: 1333-1337.
Article
CAS
PubMed
Google Scholar
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010, 62: 22-32.
Article
CAS
PubMed
Google Scholar
De Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, van Riel PL: The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology. 2012, 51: 1610-1617.
Article
CAS
PubMed
Google Scholar
Aletaha D, Smolen JS, Ward MM: Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2006, 54: 2784-2792.
Article
PubMed
Google Scholar
Aletaha D, Funovits J, Smolen JS: Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis. 2011, 70: 733-739.
Article
PubMed
Google Scholar
Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA: Prognostic factors of radiological damage in rheumatoid arthritis: A 10-year retrospective study. J Rheum. 2011, 38: 44-52.
Article
PubMed
Google Scholar
Geusens P: The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2012, 4: 225-233.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O: The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. Arthr Res Ther. 2008, 10: 208-
Article
Google Scholar
Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guérette B, Cifaldi MA, Chen N, Liu S, Landewé RB: Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2012, 0: 1-7.
Google Scholar
Boers M, van Tuyl L, van den Broek M, Kostense PJ, Allaart CF: Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis. Ann Rheum Dis. 2013, 72: 406-409.
Article
CAS
PubMed
Google Scholar